However, peeing a lot on GLP-1 medications is not a recognised side effect in official MHRA guidance
The letter emphasized several key points: Bulk compounding of semaglutide and tirzepatide is no longer permitted because FDA removed these products from the national shortage list Marketing terms such as generic Ozempic, semaglutide pills or vitamin-enhanced GLP-1 injections may violate state consumer-protection law when referring to non-approved formulations Misleading advertising of unapproved GLP-1 products falls under the Connecticut Unfair Trade Practices Act (CUTPA) Although the letter did not accuse any specific provider of wrongdoing, Connecticut placed clinics on formal notice that the GLP-1 market was under review and that enforcement would follow if risky practices continued
The scale almost demonstrated convergent validity, with a positive association with a staff measure of patient safety
Thats why many obesity specialists view these drugs as short-term tools , not permanent solutions
And who might be a candidate
If you want guidance on how to approach recovery without trial-and-error, these resources may help: Injury, Joint & Recovery Playbook decision guidance & sequencing Injury, Joint & Recovery Support Foundation supports tissue repair and healing capacity No pressure